Browsing by Subject "Aromatase inhibitor"

Article

Cancer of unknown primary site: 20 questions to be answered

Pavlidis, Nicholas; Pentheroudakis, George (2010)

Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

Article

Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pentheroudakis, George; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas (2010)

Article

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)

Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...

Article

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Kakaidi, B.; Tzallas, C. S.; Katsaraki, A.; Pavlidis, Nicholas (2001)

Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase ...

Article

Effects of hormonal treatment on lipids in patients with cancer

Filippatos, T. D.; Liberopoulos, E. N.; Pavlidis, Nicholas; Elisaf, Moses S.; Mikhailidis, Dimitri P. (2009)

Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol ...

Article

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)

Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...

Article

Metastatic breast carcinoma confined to bone: Portrait of a clinical entity

Briassoulis, E. Ch; Karavasilis, V.; Kostadima, Lida; Ignatiadis, M.; Fountzilas, George; Pavlidis, Nicholas (2004)

BACKGROUND. The current study was performed to study metastatic breast carcinoma that remains confined to bone. METHODS. The medical notes of 2514 breast carcinoma patients who were treated in 2 academic units over a 20-year ...

Article

Response

Ioannidis, J. P. A.; Mauri, D.; Polyzos, N. P.; Pavlidis, Nicholas (2007)

Article

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis

Mauri, D.; Pavlidis, Nicholas; Polyzos, N. P.; Ioannidis, J. P. A. (2006)

Background: Aromatase inhibitors and inactivators have been extensively tested in patients with advanced breast cancer, but it is unclear whether they offer any survival benefits compared with standard hormonal treatment ...